Mounjaro and Ozempic are two of the best-known names associated with type 2 diabetes and weight loss. Although the medicines share some similarities, they contain different active ingredients and do not work in exactly the same way.
Mounjaro contains tirzepatide, while Ozempic contains semaglutide. Both are generally administered once weekly, but they differ in their mechanisms, approved indications and clinical outcomes.
What is the difference between Mounjaro and Ozempic?
Semaglutide acts as a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors.
These pathways are involved in glucose regulation, appetite and food intake. Tirzepatides dual mechanism is therefore one of the main pharmacological differences between the medicines.
Are Mounjaro and Ozempic approved for weight loss?
In the United States, Mounjaro is primarily approved for adults with type 2 diabetes. Tirzepatide is marketed separately as Zepbound for chronic weight management in eligible patients.
Ozempic is also primarily a type 2 diabetes medicine, while semaglutide for weight management is marketed as Wegovy.
For this reason, discussions comparing Mounjaro and Ozempic for weight loss often reflect a broader comparison between tirzepatide and semaglutide rather than a direct comparison of the two brand indications.
Which leads to greater weight loss?
The SURMOUNT-5 trial directly compared tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes.
At 72 weeks, the average change in body weight was approximately -20.2% with tirzepatide compared with -13.7% with semaglutide.
Average waist-circumference reduction was also greater with tirzepatide: approximately 18.4 cm compared with 13.0 cm with semaglutide.
These results favored tirzepatide in this trial, but they do not mean that Mounjaro is automatically the best medicine for every patient. Importantly, the study used semaglutide doses intended for obesity management.
Do the side effects differ?
Both treatments commonly cause gastrointestinal side effects, including nausea, diarrhea, vomiting, constipation and other digestive symptoms.
In SURMOUNT-5, gastrointestinal events were the most common adverse effects in both groups and were generally mild to moderate, occurring mainly during dose escalation.
Is Mounjaro better than Ozempic for diabetes?
Choosing a diabetes medicine involves more than weight loss. Healthcare professionals consider glucose control, other medications, cardiovascular and kidney health, body weight, treatment goals and tolerability.
A difference in average weight reduction in a clinical trial does not mean every individual will experience the same difference.
Can you switch from Ozempic to Mounjaro?
A healthcare professional may recommend switching treatment in some circumstances, but patients should not switch between semaglutide and tirzepatide on their own.
The medicines have different dose-escalation schedules, and individual medical history and previous side effects must be considered.
Which is better for weight loss?
Based specifically on SURMOUNT-5, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks.
However, treatment choice depends on much more than the highest average percentage. Medical suitability, tolerability, availability, cost and local regulatory approval can all influence the decision.
Conclusion
The main difference is that Mounjaro contains tirzepatide and targets GIP and GLP-1 receptors, while Ozempic contains semaglutide and targets GLP-1 receptors.
A recent head-to-head obesity trial found greater average weight loss with tirzepatide than semaglutide, but the most appropriate treatment remains an individual medical decision.
Medical notice: This article is for educational purposes and does not recommend starting, stopping or switching prescription medicines without medical advice.
